Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | SCN4A | P35499 | 2/20 | 0.48 |
| ▸ | ALPI | P09923 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | XIAP | P98170 | 1/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | LAP3 | P28838 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17045283 | 1.00 | MMP2 (0.51) | MMP2EPHX1CYP1A2SCN4AALPI | |
| SCHEMBL11947651 | 1.00 | MMP2 (0.51) | MMP2EPHX1CYP1A2SCN4AALPI | |
| SCHEMBL17045249 | 0.86 | MMP2 (0.50) | MMP2EPHX1SCN4AALPIPKM | |
| SCHEMBL17045247 | 0.86 | MMP2 (0.50) | MMP2EPHX1SCN4AALPIPKM | |
| SCHEMBL11947649 | 0.86 | MMP2 (0.50) | MMP2EPHX1SCN4AALPIPKM | |
| SCHEMBL17045270 | 0.86 | ATM (0.41) | MMP2CYP1A2SCN4ATACR1 | |
| SCHEMBL17045267 | 0.86 | ATM (0.41) | MMP2CYP1A2SCN4ATACR1 | |
| SCHEMBL11947639 | 0.86 | ATM (0.41) | MMP2CYP1A2SCN4ATACR1 | |
| SCHEMBL17045269 | 0.85 | SLC6A4 (0.51) | CYP1A2SCN4A | |
| SCHEMBL11947660 | 0.85 | MMP2 (0.49) | MMP2EPHX1SCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255921-A1 | COMPOSITION FOR TREATING KCA3.1 CHANNEL-MEDIATED DISEASES COMPRISING PHENYLALKYL CARBAMATE COMPOUND | CELLIONBIOMED INC. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230255921-A1 | COMPOSITION FOR TREATING KCA3.1 CHANNEL-MEDIATED DISEASES COMPRISING PHENYLALKYL CARBAMATE COMPOUND | CELLIONBIOMED INC. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230255921-A1 | COMPOSITION FOR TREATING KCA3.1 CHANNEL-MEDIATED DISEASES COMPRISING PHENYLALKYL CARBAMATE COMPOUND | CELLIONBIOMED INC. (KR) | 2023-08-17 | — | — | US | disclosed |
| EP-4223291-A1 | COMPOSITION FOR TREATING KCA3.1 CHANNEL-MEDIATED DISEASES COMPRISING PHENYLALKYL CARBAMATE COMPOUND | Cellionbiomed Inc. (KR) | 2023-08-09 | — | — | EP | disclosed |
| US-20230242476-A1 | A PROCESS FOR THE PURIFICATION OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | FLAMMA SPA (IT) | 2023-08-03 | — | — | US | disclosed |
| US-20230218562-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20210113514-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS., LTD. | 2021-04-22 | — | — | US | disclosed |
| US-10888542-B2 | Aminocarbonylcarbamate compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2021-01-12 | — | — | US | disclosed |
| US-20200046674-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2020-02-13 | — | — | US | disclosed |
| EP-3110792-B1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO LTD (KR) | 2019-09-04 | — | — | EP | disclosed |
| US-20190247356-A1 | Aminocarbonylcarbamate Compounds | SK BIOPHARMACEUTICALS CO., LTD. | 2019-08-15 | — | — | US | disclosed |
| US-10314808-B2 | Aminocarbonylcarbamate compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2019-06-11 | — | — | US | disclosed |
| US-20180085337-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2018-03-29 | — | — | US | disclosed |
| US-9833432-B2 | Aminocarbonylcarbamate compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2017-12-05 | — | — | US | disclosed |
| EP-3110792-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK Biopharmaceuticals Co., Ltd. (KR) | 2017-01-04 | — | — | EP | disclosed |
| US-20160303067-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. | 2016-10-20 | — | — | US | disclosed |
| US-9403761-B2 | Aminocarbonylcarbamate compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-08-02 | — | — | US | disclosed |
| WO-2015130121-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2015-09-03 | — | — | WO | disclosed |
| US-20150246874-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2015-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230255921-A1 | COMPOSITION FOR TREATING KCA3.1 CHANNEL-MEDIATED DISEASES COMPRISING PHENYLALKYL CARBAMATE COMPOUND | KCNA3, KCNN3, KCNMA1 | MMP2 4506/4885EPHX1 1970/4885CYP1A2 3780/4885 |
| US-20190247356-A1 | Aminocarbonylcarbamate Compounds | SLC6A3, SLC6A2, SLC6A4 | MMP2 2633/4885EPHX1 3504/4885CYP1A2 1175/4885 |
| US-20150246874-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | MMP2 2633/4885EPHX1 3504/4885CYP1A2 1175/4885 |
| US-10888542-B2 | Aminocarbonylcarbamate compounds | SLC6A3, SLC6A2, SLC6A4 | MMP2 2633/4885EPHX1 3504/4885CYP1A2 1175/4885 |
| US-20160303067-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | MMP2 2633/4885EPHX1 3504/4885CYP1A2 1175/4885 |
| US-20180085337-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | MMP2 2633/4885EPHX1 3504/4885CYP1A2 1175/4885 |
| US-20210113514-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | MMP2 2633/4885EPHX1 3504/4885CYP1A2 1175/4885 |
| US-20200046674-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | MMP2 2633/4885EPHX1 3504/4885CYP1A2 1175/4885 |
| US-20230218562-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | MMP2 2633/4885EPHX1 3504/4885CYP1A2 1175/4885 |
| US-10314808-B2 | Aminocarbonylcarbamate compounds | SLC6A3, SLC6A2, SLC6A4 | MMP2 2633/4885EPHX1 3504/4885CYP1A2 1175/4885 |
| US-20230242476-A1 | A PROCESS FOR THE PURIFICATION OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | PHYKPL, BPHL, DNPEP | MMP2 1510/4885EPHX1 3363/4885CYP1A2 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.